| 949 |
Centers for Disease Control and Prevention |
Html |
en |
Shareable Media - Smoking & Tobacco Use |
Videos that highlight the dangers of tobacco use and secondhand smoke, as well as tools to help middle and high schoolers evaluate media messages. |
| social networking site | 0.641308 |
| current Infographics | 0.550183 |
| tobacco-related information | 0.614588 |
| electronic cigarettes | 0.518828 |
| visual communication | 0.48177 |
| videos | 0.338986 |
| lasting harm | 0.534485 |
| brains | 0.342957 |
| Disease Control | 0.495661 |
| Announcer | 0.341386 |
| current smoking | 0.680496 |
| potential | 0.335666 |
| common ingredient | 0.521858 |
| deaths | 0.386419 |
| brain development | 0.513599 |
| nicotine | 0.395773 |
| highly addictive drug | 0.698299 |
| U.S. Surgeon General | 0.688688 |
| tobacco-related podcasts/radio PSAs | 0.781953 |
| topic specific | 0.485425 |
| health problems | 0.959211 |
| cancers | 0.33594 |
| Browse our smoking | 0.614553 |
| Web site | 0.486771 |
| visit www.cdc.gov | 0.481856 |
|
| parents | 0.335807 |
| cause | 0.370374 |
| video | 0.335877 |
| prevention efforts | 0.480859 |
| visual representations | 0.483609 |
| accurate health information | 0.657654 |
| Information Graphics | 0.488201 |
| heart disease | 0.492187 |
| smoking | 0.77617 |
| audiences | 0.336379 |
| young users | 0.513902 |
| Science shows | 0.531308 |
| shareable digital media | 0.748094 |
| social media profiles | 0.645948 |
| MMWR | 0.336755 |
| largest decrease | 0.500911 |
| buttons | 0.375062 |
| tobacco-related gallery | 0.558504 |
| Support CDC | 0.500936 |
| Cigarette smoking | 0.644609 |
| cigarette smokers | 0.529408 |
| e-cigarettes | 0.365028 |
| risk | 0.366625 |
| major health problems | 0.892257 |
|
CLICK HERE |
| 4822 |
Centers for Disease Control and Prevention |
Html |
en |
Assessing colorectal cancer screening knowledge at tribal fairs |
null |
| Navajo adults | 0.692193 |
| Northern Navajo Medical | 0.372988 |
| Health’s Navajo | 0.313711 |
| Cervical Cancer Project | 0.204139 |
| Navajo Nation | 0.531857 |
| Navajo investigator | 0.278184 |
| Navajo Medical Center | 0.372976 |
| bilingual Navajo surveyors | 0.295941 |
| CRC screening experience | 0.372788 |
| overall CRC screening | 0.421295 |
| Annual Northern Navajo | 0.309352 |
| Navajo Division | 0.297459 |
| female Navajo surveyor | 0.268351 |
| CRC screening test | 0.375299 |
| Navajo Nation Agency | 0.355796 |
| navajo reservation | 0.340193 |
| Nation Human Research | 0.239092 |
| female Navajo investigators | 0.266707 |
| Navajo principal investigator | 0.298786 |
| National Cancer Institute | 0.205517 |
| Navajo men | 0.348522 |
| Navajo Area Indian | 0.29824 |
| CRC education | 0.284171 |
|
| project advisory committee | 0.527719 |
| CRC prevention | 0.248322 |
| Navajo women | 0.284216 |
| Arizona Cancer Center | 0.269726 |
| early-stage CRC | 0.238786 |
| colorectal cancer | 0.393913 |
| CRC screening | 0.913129 |
| Navajo Breast | 0.289837 |
| Navajo languages | 0.230058 |
| colon cancer | 0.563322 |
| Navajo research team | 0.314315 |
| annual Navajo Nation | 0.288026 |
| total knowledge score | 0.265352 |
| Navajo | 0.84888 |
| CRC risk factors | 0.496821 |
| male Navajo surveyor | 0.267404 |
| male Navajo investigators | 0.265714 |
| ........ | 0.455441 |
| Navajo Nation Human | 0.431765 |
| Navajo project | 0.340311 |
| Navajo respondents | 0.419666 |
| CRC knowledge survey | 0.433598 |
| Navajo population | 0.237316 |
|
CLICK HERE |
| 5646 |
Centers for Disease Control and Prevention |
Html |
en |
Phosphoric acid - NIOSH Pocket Guide to Chemical Hazards |
null |
| MPEG | 0.378858 |
| search | 0.263099 |
| PDF | 0.261307 |
| PPT | 0.446092 |
|
| DOC | 0.368812 |
| information | 0.262482 |
| different file formats | 0.938484 |
| page | 0.276773 |
|
CLICK HERE |
| 7932 |
Centers for Disease Control and Prevention |
Html |
en |
Published Reports of Delayed Hemolytic Anemia AfterTreatment with Artesunate for Severe Malaria - Worldwide,2010-2012 |
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. |
| red blood cells | 0.456338 |
| hemolysis | 0.559048 |
| CDC Malaria Branch | 0.540567 |
| Materiel Development Activity | 0.465429 |
| reported parasitemia | 0.452963 |
| first-line treatment | 0.473955 |
| ring-infected erythrocyte surface | 0.452303 |
| unparasitized RESA-positive RBCs | 0.479808 |
| World Health Organization | 0.465405 |
| nonendemic countries | 0.459615 |
| artesunate | 0.568941 |
| mean cumulative dose | 0.503754 |
| patients | 0.604793 |
| severe anemia | 0.475981 |
| Paul M. Arguin | 0.456851 |
| packed RBCs | 0.463338 |
| mean hemoglobin nadir | 0.489566 |
| parasite clearance | 0.523007 |
| delayed hemolysis | 0.477318 |
| treatment | 0.538183 |
| delayed hemolytic events | 0.529144 |
| severe malaria | 0.914536 |
| United States | 0.774646 |
| mean highest parasitemia | 0.465792 |
|
| good manufacturing practice | 0.454522 |
| artesunate-treated RBCs | 0.459786 |
| delayed postartesunate treatment | 0.485835 |
| peer-reviewed medical literature | 0.462664 |
| manufacturing site assessment | 0.454143 |
| artesunate therapy | 0.553437 |
| severe malaria patients | 0.556323 |
| travel-associated severe malaria | 0.543841 |
| initial clinical improvement | 0.458298 |
| cases | 0.466489 |
| CDC IND protocol | 0.462256 |
| RBCs | 0.495752 |
| complete parasite clearance | 0.45911 |
| typical hemoglobin nadir | 0.475094 |
| artesunate IND protocol | 0.482146 |
| U.S. artesunate | 0.457063 |
| healthy RBCs | 0.457493 |
| additional case reports | 0.462224 |
| acute malaria | 0.499959 |
| glucose-6-phosphate dehydrogenase deficiency | 0.45421 |
| multiple hemoglobin measurements | 0.481867 |
| elevated lactate dehydrogenase | 0.460566 |
| delayed hemolytic anemia | 0.539312 |
| Melissa Briggs | 0.454573 |
|
CLICK HERE |
| 8848 |
Centers for Disease Control and Prevention |
Html |
en |
Risk Assessment and Biosafety Level RecommendationsInfluenza A H7N9 |
Interim Risk Assessment and Biosafety Level Recommendations for Working With Influenza A(H7N9) Viruses - CDC |
| H7N9 viruses | 0.486755 |
| low-pathogenicity avian influenza | 0.521338 |
| avian influenza | 0.724031 |
| antiviral agents | 0.499452 |
| laboratory workers | 0.501763 |
| avain influenza | 0.49607 |
| avian influenza viruses | 0.594765 |
| novel influenza | 0.565285 |
| human influenza viruses | 0.5897 |
| wild type influenza | 0.556002 |
| influenza virus vaccine | 0.536097 |
| J.J. Influenza virus | 0.529153 |
| influenza A viruses | 0.528594 |
| laboratory personnel | 0.495254 |
| primary containment device | 0.483714 |
| influenza disease | 0.522104 |
| convalescent serum samples | 0.488378 |
| H7N9 virus transmission | 0.480391 |
| H7 subtype viruses | 0.550222 |
| pathogenic avian influenza | 0.571665 |
| wild type virus | 0.484115 |
| potential occupational exposure | 0.483077 |
| seasonal influenza vaccine | 0.53685 |
|
| avian influenza H7N3 | 0.52367 |
| respiratory protection | 0.514977 |
| airborne influenza virus | 0.52761 |
| Anonymous. Avian influenza | 0.521121 |
| avian influenza lineage | 0.550832 |
| influenza vaccines | 0.508998 |
| avian influenza virus | 0.571145 |
| H7N3 influenza vaccine | 0.526967 |
| inactivated avian influenza | 0.523841 |
| J. Avian influenza | 0.523507 |
| uncomplicated influenza illness | 0.520033 |
| Infectious influenza virus | 0.551295 |
| influenza H7 virus | 0.545133 |
| biological safety cabinets | 0.495055 |
| virus infection | 0.481396 |
| human infections | 0.504265 |
| influenza viruses | 0.636895 |
| laboratory | 0.536054 |
| H9N2 avian influenza | 0.541245 |
| virulent H5N1 influenza | 0.508764 |
| Eurasian avian influenza | 0.54069 |
| current seasonal influenza | 0.517752 |
| Eurasian H7 viruses | 0.479799 |
|
CLICK HERE |
| 9365 |
Centers for Disease Control and Prevention |
Html |
es |
Prevalencia de ciertos factores de riesgo de enfermedades crónicas no transmisibles en Jordania: Resultados de la Encuesta del 2007 sobre Vigilancia de Factores de Riesgo del Comportamiento en Jordania |
CDC - Wide Page example description goes here |
| Brown DW | 0.563983 |
| Zindah M | 0.557486 |
| Organización Mundial | 0.540234 |
| disease risk factors | 0.745965 |
| Walke H | 0.559141 |
| risk factor | 0.929172 |
| reportó tensión | 0.539732 |
| adultos jordanos | 0.575603 |
|
| Factor Surveillance Survey | 0.702162 |
| Hadaddin R | 0.557377 |
| Belbeisi A | 0.556087 |
| Jordan Behavioral Risk | 0.754267 |
| salud pública | 0.740807 |
| determinadas afecciones | 0.588898 |
| reportó hipertensión | 0.598322 |
| Chronic Dis | 0.58998 |
|
CLICK HERE |
| 11010 |
Centers for Disease Control and Prevention |
Html |
en |
Meningococcal | Technical and Clinical Info | CDC |
Meningococcal Disease: Technical and Clinical Information Chart and Resources on Meningococcal Vaccination. |
| small portion | 0.375984 |
| PNH | 0.314781 |
| stiff neck | 0.378971 |
| long-term disabilities | 0.366953 |
| case patients | 0.364867 |
| incomplete protection | 0.363431 |
| increased risk | 0.375259 |
| paroxysmal nocturnal hemoglobinuria | 0.422901 |
| adolescents | 0.326555 |
| Neisseria meningitidis | 0.391156 |
| incidence rate | 0.368874 |
| brain damage | 0.366203 |
| age groups | 0.410491 |
| eculizumab patients | 0.360297 |
| graph | 0.326357 |
| nervous system problems | 0.368153 |
| meningococcal disease | 0.949259 |
| highest risk | 0.370507 |
| late 1990s | 0.372462 |
| medical conditions | 0.416274 |
| young adults | 0.369709 |
| higher rates | 0.363317 |
| sepsis | 0.317388 |
| meningococcal meningitis cases | 0.680646 |
| invasive meningococcal disease | 0.616601 |
|
| United States | 0.441175 |
| throat secretions | 0.37286 |
| total cases | 0.370758 |
| prophylaxis | 0.335637 |
| hemolytic uremic syndrome | 0.422926 |
| meningococcal vaccines | 0.550869 |
| lengthy contact | 0.365167 |
| sub-Saharan Africa | 0.374303 |
| reportable condition | 0.366864 |
| following groups | 0.35975 |
| close contact | 0.370464 |
| meningococcal vaccination recommendations | 0.594263 |
| local health departments | 0.414449 |
| meningococcal disease surveillance | 0.618337 |
| highest rates | 0.372975 |
| people | 0.361834 |
| certain medical conditions | 0.413526 |
| rash | 0.316019 |
| meningitis belt | 0.375999 |
| Recent data | 0.36297 |
| close contacts | 0.427891 |
| meningococcal bacteria | 0.569786 |
| household | 0.324215 |
| multiple serogroups | 0.375539 |
|
CLICK HERE |
| 11029 |
Centers for Disease Control and Prevention |
Html |
en |
The 25th Anniversary of the Discovery of the Hepatitis CVirus: Looking Back to Look Forward | Public Health Grand Rounds 'CDC |
Pre-Exposure Prophylaxis for Prevention of HIV - CDC |
| Health Grand Rounds | 0.909643 |
| blood products | 0.494934 |
| STD | 0.415781 |
| CDC | 0.435582 |
| MPH | 0.46096 |
| San Francisco Department | 0.541103 |
| HCV-infected persons | 0.569007 |
| Phillip O. Coffin | 0.546216 |
| therapeutic advances | 0.568859 |
| Susan Laird | 0.478095 |
| blood borne infection | 0.60512 |
| spite | 0.420783 |
| successes | 0.416787 |
| MD | 0.46198 |
| Recent therapeutic advances | 0.562618 |
| National Center | 0.481336 |
| TB Prevention | 0.484668 |
| hepatitis C. | 0.561132 |
| isolation | 0.415251 |
| Viral Hepatitis | 0.592155 |
| Stanhope Bayne Jones | 0.55838 |
| Curative Era | 0.484581 |
| decrease | 0.419219 |
| Communications Director | 0.484563 |
| Public Health Grand | 0.573476 |
|
| David Thomas | 0.479884 |
| new screening guidelines | 0.553442 |
| new infections | 0.486583 |
| Public Health | 0.706895 |
| HCV infection | 0.774925 |
| United States | 0.488021 |
| progression | 0.415064 |
| virus | 0.429021 |
| Hopkins School | 0.477387 |
| individual outcomes | 0.483518 |
| Deputy Scientific Director | 0.553539 |
| pivotal role | 0.501905 |
| Public Health University | 0.554535 |
| testing methods | 0.483328 |
| implementation | 0.415197 |
| rates | 0.415124 |
| Thorpe | 0.41529 |
| p.m | 0.419634 |
| Medicine | 0.422323 |
| California San Francisco | 0.54071 |
| Infectious Diseases Johns | 0.542439 |
| Substance Use Research | 0.476354 |
| discovery | 0.415266 |
| John Iskander | 0.487673 |
|
CLICK HERE |
| 15576 |
Centers for Disease Control and Prevention |
Html |
en |
Flu Season Continues; Seniors Hit Hard |
Flu Season Continues; Seniors Hit Hard. CDC Urges People 65 and Older to Seek Treatment for Flu Symptoms Promptly. |
| epidemic threshold | 0.569618 |
| CDC | 0.646044 |
| flu cough | 0.524297 |
| flu infection | 0.624233 |
| flu activity | 0.676447 |
| vaccine supplies | 0.457487 |
| Finelli | 0.985575 |
| vaccination status | 0.462258 |
| high risk patients | 0.579133 |
| human immune systems | 0.538722 |
| intensive care unit | 0.525973 |
| seasonal influenza | 0.553525 |
| Flu Vaccine Finder | 0.647865 |
| 2007-2008 influenza season | 0.678035 |
| overall downward trend | 0.533683 |
| severity indicators | 0.46026 |
| high risk | 0.731277 |
| latest FluView report | 0.592136 |
| antiviral medications | 0.492983 |
| highest hospitalization rate | 0.562766 |
| influenza | 0.983684 |
| hospitalization rate | 0.651809 |
| medical treatment | 0.515185 |
| seniors | 0.711642 |
| flu-related deaths | 0.499471 |
|
| overall picture | 0.454391 |
| flu vaccine | 0.651514 |
| influenza-like illness | 0.542428 |
| H3N2-predominant influenza season | 0.696939 |
| past severe seasons | 0.543792 |
| flu-related hospitalizations | 0.711639 |
| CDC’s Influenza | 0.6116 |
| Cities Mortality Reporting | 0.55812 |
| Early vaccine effectiveness | 0.565198 |
| heaviest toll | 0.45996 |
| flu-like symptoms | 0.597518 |
| Dr. Lyn Finelli | 0.754052 |
| antiviral drugs | 0.572066 |
| people | 0.798366 |
| death indicators | 0.461857 |
| flu | 0.87047 |
| antiviral treatment | 0.587698 |
| influenza viruses | 0.525937 |
| key illness indicator | 0.560335 |
| flu season | 0.672832 |
| Outbreak Response Team | 0.56903 |
| flu-related hospitalization | 0.537271 |
| Influenza-related hospitalizations | 0.535668 |
| rapid test results | 0.560657 |
|
CLICK HERE |
| 15654 |
Centers for Disease Control and Prevention |
Html |
null |
Zika Virus |
Zika Virus - CDC Newsroom |
|
|
CLICK HERE |